Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Thursday morning, Benzinga reports. JMP Securities currently has a $5.00 target price on the stock.

TSHA has been the topic of several other reports. Chardan Capital restated a buy rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday. Piper Sandler started coverage on Taysha Gene Therapies in a research report on Tuesday, April 9th. They issued an overweight rating and a $9.00 price target on the stock. Jefferies Financial Group restated a buy rating and issued a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday, May 14th. Cantor Fitzgerald restated an overweight rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday. Finally, Canaccord Genuity Group restated a buy rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of Buy and a consensus price target of $7.00.

Taysha Gene Therapies Stock Down 7.1 %

Shares of TSHA opened at $2.76 on Thursday. The firm has a market capitalization of $516.18 million, a price-to-earnings ratio of -5.63 and a beta of 0.50. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38. The business’s fifty day moving average price is $3.00 and its two-hundred day moving average price is $2.38. Taysha Gene Therapies has a 52 week low of $0.50 and a 52 week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same period last year, the company earned ($0.28) EPS. On average, analysts predict that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently added to or reduced their stakes in the business. Howard Capital Management Inc. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at about $25,000. Victory Capital Management Inc. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at about $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter valued at about $38,000. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies in the 1st quarter valued at about $69,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.